About Us

Overview

Company Overview

ROX® Medical has developed an implantable device and therapy intended to treat uncontrolled high blood pressure. Blood pressure reduction is achieved by diverting a small amount of blood flow from the arterial system into the venous system.

The ROX Coupler is a small stent-like device that is placed between the artery and vein located in the upper thigh. The Coupler is about the size of a dime and is easily placed using standard catheter techniques.

ROX Medical is conducting the CONTROL HTN-2 clinical trial in the United States for hypertension (visit www.controlhtn2.com for more information). The ROX Medical Coupler is commercially available in Europe under CE mark.

team

Management Team

Steve Weinstein, Chief Executive Officer

Steve Weinstein serves as Chief Executive Officer at ROX Medical. For over 20 years, Steve has worked with innovative start-up companies as an entrepreneur and venture capital investor. Steve recently served as Managing Director at the Novartis Venture Fund, leading its medical technology investing, as well as investing in biotech. Prior to Novartis, Steve was a Principal at Prism Venture Partners, and a Kauffman Fellow with Mid-Atlantic Venture Funds. He has served on many boards including: Ablation Frontiers (acquired by Medtronic), Autonomic Technologies Inc., Sensitech (acquired by Carrier/UTX), Sonitus Medical, and Visiogen (acquired by Abbott). He currently serves on the Innovation Advisory Board of Partners Healthcare and is a member of the Virginia GAP BioLife Fund Investment Committee. Steve holds an MBA from University of Michigan and a BS in mechanical engineering from Columbia University.


Rodney Brenneman, Chief Technology Officer

Rodney Brenneman has 24 years of experience in the medical device industry. He co-founded ROX Medical in 2004. Prior to ROX Medical Mr. Brenneman worked for USGI Medical as Vice President of R&D. At USGI he led a team of nine engineers and technicians to develop devices for endo-luminal GI surgery. Mr. Brenneman co-founded TheraCardia in 1998 and served as VP of R&D and Operations until 2003. Prior to 1998, Mr. Brenneman worked for Vesica Medical, acquired by Boston Scientific, Corp in 1996 and Advanced Surgical Intervention acquired by Boston Scientific, Corp in 1993. Mr. Brenneman has also done considerable consulting for very early stage medical device companies in a wide variety of specialties including Cardiology, Orthopedics, Urology, Opthamology, Neurology and Interventional Radiology.


Paul Sobotka, MD, Chief Scientific Officer

Paul Alan Sobotka, M.D., F.A.C.C., F.A.C.P., F.A.H.A., Chief Medical Officer of ROX, Inc. Graduated from Stanford University with degree in Chemistry and obtained his Medical Degree from the University of Illinois College of Medicine. Dr. Sobotka completed training in Internal Medicine at The University of Michigan, followed by specialty training in cardiovascular diseases at Northwestern University.  He holds an appointment as Clinical Professor of Medicine/Cardiology at The Ohio State University.

Dr. Sobotka has authored nearly 200 peer reviewed manuscripts and book chapters including manuscripts published in: The Journal Clinical Investigation, American Journal of Physiology, The New England Journal of Medicine, Circulation: The Lancet, Circulation: Heart Failure, Journal of Congestive Failure, Hypertension, Journal of Hypertension, Journal of the American Society of Nephrology, and Journal of Congestive Heart Failure.


Chas McKhann, Chief Commercial Officer

Chas McKhann serves as Chief Commercial Officer at ROX Medical. For more than 20 years, Chas has worked with medical technology companies on successfully developing and building adoption of innovative therapies. Most recently, Chas was Chief Commercial Officer at TORAX Medical where he oversaw a rapid acceleration in utilization and sales of the LINX® Reflux Management System for patients with GERD, resulting in the sale of Torax to Johnson & Johnson. Chas has also served as Chief Commercial Officer at Intersect ENT as well as CEO of a medical device company working on a novel therapy for sleep apnea. Previously, Chas’s roles have included Worldwide VP of Marketing for the Boston Scientific Cardiac Rhythm Management division and global Director for the CYPHER® sirolimus eluting coronary stent at Johnson & Johnson. Chas earned his BA and MBA degrees from Stanford University.


Peter Balmforth, Director of Therapy Development, Education, and Sales

Peter Balmforth is the Director of Therapy Development, Education and Sales for Europe. Bringing 10 years of medical device experience,  Peter joined ROX Medical in 2010 to lead the European market. Prior to ROX, he was Country Manager for both Atritech and Ablation Frontiers, both exited in successful mergers with BSX and Medtronic. Previously he served as Territory Manager for Endocardial Solutions, Inc., and post acquisition by St. Jude Medical, he continued his service as Product Manager.


Chris Yelley, Director of Operations

Chris Yelley is the Director of Operations for ROX Medical. With over 30 years of experience in the medical device industry Chris joined ROX Medical in 2008 to lead the manufacturing and operations efforts. Prior to joining ROX Medical Chris was with ev3 Neurovascular where he led the Process Development team. From 2000 through 2005 Chris served as Vice President of Operations with IntraLuminal Therapeutics in Carlsbad, CA. He has lead operations, quality, engineering and manufacturing teams both nationally and internationally, developing lean and efficient processes and programs for, MRI Interventions, Intravascular Research Limited and Advanced Cardiovascular Systems (Guidant).

roxmedicalusAbout Us